FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059631907> ?p ?o ?g. }

• W2059631907 endingPage "173" @default.
• W2059631907 startingPage "164" @default.
• W2059631907 abstract "To evaluate the efficacy of the cyclooxygenase-2 selective inhibitor celecoxib in treating patients with psoriatic arthritis (PsA) in flare.This 12-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study compared the efficacy and safety of celecoxib 400 mg (n=201) or celecoxib 200 mg (n=213) once daily (qd) with placebo (n=194) in treating the signs and symptoms of PsA in flare. The primary efficacy measure was the number of patients responding to treatment according to the American College of Rheumatology Responders Index 20% (ACR-20) at week 12. Efficacy and safety were assessed for all randomized patients who received at least 1 dose of study medication.At the week-12 primary endpoint, approximately 50% of patients in each treatment group were responders according to the ACR-20 criteria, and no statistically significant treatment differences between treatment groups were observed. However, at week 2, the ACR-20 response rates for the celecoxib 400 mg (49%) and 200 mg (39%) groups were significantly higher than for the placebo group (28%) (P<0.001 and P=0.016, respectively). Within the celecoxib 400 mg group, ACR-20 response rates were similar at weeks 2, 6 (46%), and 12 (49%). In contrast, in the celecoxib 200 mg and placebo treatment groups, ACR-20 response rates increased 7 and 16%, respectively, from week 2 to week 6, and remained relatively unchanged from week 6 to week 12. There were no statistically significant differences in ACR-20 response rates between the celecoxib 400 mg and 200 mg groups at any time point. Treatment with celecoxib 200 and 400 mg qd was statistically superior to placebo treatment at weeks 2 and 6 for Patient's Assessment of Arthritis Pain. Both doses of celecoxib were well tolerated.Celecoxib 400 mg and 200 mg qd were efficacious and well tolerated in treating the signs and symptoms of PsA in flare after 2 weeks of treatment. However, although the clinical effects of celecoxib 400 mg and 200 mg qd were observed for 12 weeks, there was a high placebo response at these time points, and there were no differences relative to placebo treatment at week 12." @default.
• W2059631907 created "2016-06-24" @default.
• W2059631907 creator A5043724986 @default.
• W2059631907 creator A5073316716 @default.
• W2059631907 creator A5077319719 @default.
• W2059631907 creator A5082669130 @default.
• W2059631907 creator A5089760100 @default.
• W2059631907 date "2007-12-01" @default.
• W2059631907 modified "2023-10-18" @default.
• W2059631907 title "A Comparison of the Efficacy and Safety of Celecoxib 200 mg and Celecoxib 400 mg Once Daily in Treating the Signs and Symptoms of Psoriatic Arthritis" @default.
• W2059631907 cites W1967003302 @default.
• W2059631907 cites W1983104516 @default.
• W2059631907 cites W1983577477 @default.
• W2059631907 cites W1983629747 @default.
• W2059631907 cites W1994647690 @default.
• W2059631907 cites W2000190640 @default.
• W2059631907 cites W2007517418 @default.
• W2059631907 cites W2020869366 @default.
• W2059631907 cites W2030319458 @default.
• W2059631907 cites W2034666462 @default.
• W2059631907 cites W2035612894 @default.
• W2059631907 cites W2038089071 @default.
• W2059631907 cites W2049021766 @default.
• W2059631907 cites W2058882501 @default.
• W2059631907 cites W2067327580 @default.
• W2059631907 cites W2078157933 @default.
• W2059631907 cites W2083180635 @default.
• W2059631907 cites W2088158803 @default.
• W2059631907 cites W2093455167 @default.
• W2059631907 cites W2102632616 @default.
• W2059631907 cites W2107274677 @default.
• W2059631907 cites W2111639672 @default.
• W2059631907 cites W2115012618 @default.
• W2059631907 cites W2119669579 @default.
• W2059631907 cites W2129412734 @default.
• W2059631907 cites W2135488438 @default.
• W2059631907 cites W2139788459 @default.
• W2059631907 cites W2150915843 @default.
• W2059631907 cites W2163756514 @default.
• W2059631907 doi "https://doi.org/10.1016/j.semarthrit.2007.03.004" @default.
• W2059631907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17570469" @default.
• W2059631907 hasPublicationYear "2007" @default.
• W2059631907 type Work @default.
• W2059631907 sameAs 2059631907 @default.
• W2059631907 citedByCount "35" @default.
• W2059631907 countsByYear W20596319072012 @default.
• W2059631907 countsByYear W20596319072013 @default.
• W2059631907 countsByYear W20596319072014 @default.
• W2059631907 countsByYear W20596319072015 @default.
• W2059631907 countsByYear W20596319072016 @default.
• W2059631907 countsByYear W20596319072017 @default.
• W2059631907 countsByYear W20596319072018 @default.
• W2059631907 countsByYear W20596319072020 @default.
• W2059631907 countsByYear W20596319072021 @default.
• W2059631907 countsByYear W20596319072023 @default.
• W2059631907 crossrefType "journal-article" @default.
• W2059631907 hasAuthorship W2059631907A5043724986 @default.
• W2059631907 hasAuthorship W2059631907A5073316716 @default.
• W2059631907 hasAuthorship W2059631907A5077319719 @default.
• W2059631907 hasAuthorship W2059631907A5082669130 @default.
• W2059631907 hasAuthorship W2059631907A5089760100 @default.
• W2059631907 hasConcept C126322002 @default.
• W2059631907 hasConcept C142724271 @default.
• W2059631907 hasConcept C168563851 @default.
• W2059631907 hasConcept C197934379 @default.
• W2059631907 hasConcept C198451711 @default.
• W2059631907 hasConcept C203092338 @default.
• W2059631907 hasConcept C204787440 @default.
• W2059631907 hasConcept C27081682 @default.
• W2059631907 hasConcept C2776260265 @default.
• W2059631907 hasConcept C2776467144 @default.
• W2059631907 hasConcept C2777077863 @default.
• W2059631907 hasConcept C71924100 @default.
• W2059631907 hasConcept C90924648 @default.
• W2059631907 hasConceptScore W2059631907C126322002 @default.
• W2059631907 hasConceptScore W2059631907C142724271 @default.
• W2059631907 hasConceptScore W2059631907C168563851 @default.
• W2059631907 hasConceptScore W2059631907C197934379 @default.
• W2059631907 hasConceptScore W2059631907C198451711 @default.
• W2059631907 hasConceptScore W2059631907C203092338 @default.
• W2059631907 hasConceptScore W2059631907C204787440 @default.
• W2059631907 hasConceptScore W2059631907C27081682 @default.
• W2059631907 hasConceptScore W2059631907C2776260265 @default.
• W2059631907 hasConceptScore W2059631907C2776467144 @default.
• W2059631907 hasConceptScore W2059631907C2777077863 @default.
• W2059631907 hasConceptScore W2059631907C71924100 @default.
• W2059631907 hasConceptScore W2059631907C90924648 @default.
• W2059631907 hasIssue "3" @default.
• W2059631907 hasLocation W20596319071 @default.
• W2059631907 hasLocation W20596319072 @default.
• W2059631907 hasOpenAccess W2059631907 @default.
• W2059631907 hasPrimaryLocation W20596319071 @default.
• W2059631907 hasRelatedWork W1546114942 @default.
• W2059631907 hasRelatedWork W1758202136 @default.
• W2059631907 hasRelatedWork W2086095088 @default.
• W2059631907 hasRelatedWork W2151280501 @default.
• W2059631907 hasRelatedWork W2769592731 @default.
• W2059631907 hasRelatedWork W2783466784 @default.

• next